Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Operating Leases (2021 - 2025)

Historic Operating Leases for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $2.4 million.

  • Aligos Therapeutics' Operating Leases fell 5707.84% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 5707.84%. This contributed to the annual value of $4.8 million for FY2024, which is 3746.74% down from last year.
  • As of Q3 2025, Aligos Therapeutics' Operating Leases stood at $2.4 million, which was down 5707.84% from $3.2 million recorded in Q2 2025.
  • Over the past 5 years, Aligos Therapeutics' Operating Leases peaked at $11.3 million during Q4 2021, and registered a low of $2.4 million during Q3 2025.
  • Moreover, its 5-year median value for Operating Leases was $8.6 million (2023), whereas its average is $7.8 million.
  • As far as peak fluctuations go, Aligos Therapeutics' Operating Leases soared by 656.0% in 2022, and later crashed by 5707.84% in 2025.
  • Over the past 5 years, Aligos Therapeutics' Operating Leases (Quarter) stood at $11.3 million in 2021, then fell by 18.48% to $9.2 million in 2022, then fell by 16.66% to $7.7 million in 2023, then tumbled by 37.47% to $4.8 million in 2024, then tumbled by 50.36% to $2.4 million in 2025.
  • Its Operating Leases stands at $2.4 million for Q3 2025, versus $3.2 million for Q2 2025 and $4.3 million for Q1 2025.